| Deal value | $210M |
|---|---|
| Share of market cap | 52.1% |
| Share of annual revenue | 25.5% |
Key highlights
- $210 million cash consideration plus the value of existing inventory at the time of closing
- Divested assets include the Foresight Carrier Screen, Prequel Prenatal Screen, and SneakPeek Early Gender Test
- Labcorp expects the acquired business to contribute approximately $160 million in revenue in its first year
- Transaction is projected to close by early 2027 following regulatory clearance under the Hart-Scott-Rodino Act
- Strategic reallocation focuses resources on high-growth cancer diagnostics and precision medicine segments
What Is Being Divested?
The transaction involves the transfer of Myriad Genetics' entire prenatal health testing business unit to Laboratory Corporation of America. This includes laboratory-developed tests such as the Foresight Carrier Screen, Prequel Prenatal Screen, and the FirstGene 4-in-1 Prenatal Screen, alongside the consumer-facing SneakPeek Early Gender Test. Over the last 12 months, this portfolio served more than 600,000 patients and was utilized by thousands of healthcare providers. Upon closing, Labcorp will assume certain assets and liabilities related to these operations, while offering comparable employment terms to the segment's existing staff to ensure operational continuity for patients and physicians.
Strategic Rationale
This divestiture is the outcome of a disciplined strategic review process aimed at narrowing Myriad’s operational focus. By exiting the reproductive health market, the company intends to concentrate its capital and scientific expertise on its cancer care continuum. Management anticipates that this transition will be accretive to both revenue growth and profitability while significantly strengthening the balance sheet. The move aligns with a broader trend of portfolio optimization in the diagnostics sector, where companies are shedding non-core assets to double down on specialized high-margin medical fields like oncology and precision medicine where molecular insights drive long-term value.
Financial and Operational Impact
- Labcorp projects the acquired assets will reach average diagnostics segment margins by the end of the second year
- Myriad Genetics will enter into a transition services agreement and a patent license agreement at closing
- Transaction is expected to be slightly accretive to Labcorp's adjusted earnings within the first year of integration
- Sale proceeds will support Myriad's continued investment in strategic oncology priorities and debt management
- A termination fee may be applicable if the deal is cancelled under specific regulatory circumstances
Up 32.3% since our story on 20 Oct: $4.21 when we broke it → $5.57 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $4.21 |
|---|---|
| 20 Oct | $5.54 |
| 21 Oct | $5.57 |
| 22 Oct | $5.76 |
| 23 Oct | $5.82 |
| 26 Oct | $6.02 |
| 27 Oct | $6.29 |
| 28 Oct | $6.63 |
| 29 Oct | $6.67 |
| 30 Oct | $6.35 |
| 2 Nov | $5.85 |
| 3 Nov | $6.04 |
| 4 Nov | $6.02 |
| 5 Nov | $6.29 |
| 6 Nov | $5.92 |
| 9 Nov | $5.74 |
| 10 Nov | $5.67 |
| 11 Nov | $5.72 |
| 12 Nov | $5.68 |
| 13 Nov | $5.66 |
| 16 Nov | $5.57 |
Business Overview
Following the sale, Myriad Genetics will focus exclusively on its remaining molecular diagnostic and precision medicine platforms. The company develops tests that assess the risk of disease progression and guide treatment decisions across various medical specialties. For the full year 2026, Myriad has projected revenue in the range of $770 million to $790 million. The company remains headquartered in Salt Lake City and continues to leverage its proprietary genetic databases to support earlier disease detection and lower healthcare costs through more precise medical interventions in the cancer care space.
Management commentary
“This transaction is expected to be accretive to Myriad’s revenue growth and profitability, while meaningfully strengthening the balance sheet to support continued investment in our strategic priorities tied to the cancer care continuum and long-term value creation.”
“By combining these capabilities with Labcorp's operational strength and high-quality women's health portfolio, we aim to improve outcomes, expand access to advanced screening solutions and enhance the patient and provider experience.”
| Share price | $4.21 |
|---|---|
| Market cap | $403M |
| Revenue (annual) | $824M |
| 1-month price change | +1.69% |
| Sector | HealthcareDiagnostics & Research |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Myriad Genetics, Inc. announcing an asset purchase agreement to sell its prenatal health business to Laboratory Corporation of America.
Track MYRIAD GENETICS INC live
Get the next MYRIAD GENETICS INC SEC filing seconds after it lands.



